A validation study of an Italian version of the brief pain inventory (Breve questionario per la valutazione del dolore)

Caraceni, Augusto; Mendoza, Tito R.; Mencaglia, Emanuela; Baratella, Claudio; Edwards, Katherine R.; Forjaz, Maria João; Martini, Cinzia; Serlin, Ronald C.; Conno, F. De; Cleeland, Charles S.

doi:10.1016/0304-3959(95)00156-5

Cited by 167 publications

(157 citation statements)

References 13 publications

Supporting

Mentioning

144

Contrasting

Order By: Relevance

“…The advantages of such a scale have been demonstrated in previous validation studies of the Brief Pain Inventory 10,26 and in comparisons made across culturally and linguistically varied groups in several countries. 18 Also, the 0 -10 scale of the MDASI-C is easily used in conjunction with modern technology, such as computer-aided interactive voice telephone systems, electronic mail, and the Internet, and this feature gives both hospitals and patients the flexibility to communicate efficiently.…”

Section: Discussionmentioning

confidence: 99%

Chinese version of the M. D. Anderson Symptom Inventory

Wang

Guo

et al. 2004

Cancer

Self Cite

180

View full text Add to dashboard Cite

BACKGROUNDSymptom management is an essential component of cancer treatment for patients of every culture and nationality. Symptom assessment depends on subjective reporting, mandating linguistically equivalent versions of symptom assessment scales. Because disease‐related and treatment‐related symptoms most often occur in clusters, there is a global need for a standardized multiple‐symptom assessment tool.METHODSThe authors sought to validate the Chinese version of the M. D. Anderson Symptom Inventory (MDASI‐C) by enrolling patients who had received various diagnoses of and different types of treatment for cancer (n = 249) in a cross‐sectional symptom study conducted at an urban cancer center in China.RESULTSFactor analysis identified 2 underlying constructs, general symptoms and gastrointestinal symptoms, which had Cronbach alpha coefficients of 0.86 and 0.84, respectively. These results were consistent with English‐ and Japanese‐language MDASI validation studies. Known‐group validity was supported by the MDASI‐C's ability to detect significant differences in symptom and interference levels according to Eastern Cooperative Oncology Group performance status (ECOG PS; P < 0.001) and chemotherapy status (P < 0.05). Fifty‐five percent of the study cohort had ≥ 1 symptom that was considered severe (score ≥ 7 on a 0–10 scale). ECOG PS was strongly associated with symptom burden (total interference score: R2 = 0.26; P < 0.001). Fatigue, sadness, drowsiness, and lack of appetite accounted for most of the variability in the total interference score (R2 = 0.49; P < 0.05).CONCLUSIONSThe authors demonstrated that the MDASI‐C is a valid, reliable, and concise tool for measuring symptom severity and interference with functioning in Chinese cancer patients. Cancer 2004. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Chinese version of the M. D. Anderson Symptom Inventory

Wang

Guo

et al. 2004

Cancer

Self Cite

180

View full text Add to dashboard Cite

show abstract

“…The BPI has been administered and assessed for validity in several languages including Spanish, French, Japanese, Chinese, Italian, Hindi, German, Greek, and Vietnamese. [17][18][19][20][21][22][23] The BPI was administered in the patient's native language in any case where a validated translation existed. When no such translation existed, then it was administered with translation assistance.…”

mentioning

confidence: 99%

Racial differences in pain during 1 year among women with metastatic breast cancer

Castel

Saville

DePuy

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. Longitudinal tumor‐specific studies of cancer pain across the disease trajectory provide insight into the course of pain. Information on pain predictors refines our understanding of patients with greatest distress and need. METHODS. The authors studied 1124 women with metastatic breast cancer and bone metastases, all of whom received standard treatment in an international clinical trial conducted from October 1998 to January 2001. The Brief Pain Inventory (BPI) was administered repeatedly during the course of 1 year. Hazard models were fitted to identify baseline and time‐dependent covariates as predictors of pain worsening within cumulative 80‐day intervals during the year. RESULTS. Increased severe pain hazards were associated with non‐Caucasian race (hazard ratio [HR] = 2.52; 95% CI, 1.69–3.76), restricted performance status (HR = 1.73; 95% CI, 1.13–2.64), and radiation therapy in a previous interval (HR = 2.86; 95% CI, 1.61‐5.09). Estimated cumulative rates for not yet reaching a BPI score of 7 or above ranged from 0.79 (0.72–0.85) in the first interval to 0.64 (0.55–0.74) in the last interval for non‐Caucasian women, whereas these rates ranged from 0.91 (0.89–0.93) to 0.84 (0.81–0.87) for Caucasian women. CONCLUSIONS. By using a time‐to‐event hazards analysis for cancer symptom data, the authors demonstrated that non‐Caucasian race predicted poorer pain control among women with metastatic breast cancer. Disparity findings from cross‐sectional studies were confirmed. Pain management strategies should take race into account as a risk factor for worsening pain outcomes, and further investigation should seek to uncover and resolve the reasons for this obvious disparity. Cancer 2008. © 2007 American Cancer Society.

show abstract

“…To assess the impact of pain on quality of life (QoL), a non-validated, adapted version of the Brief pain inventory 26 was used. Patients were asked to indicate a score from 1 (pain does not interfere) to 10 (pain completely interferes) for 7 items (sleep, appetite, walking, personal care, activities, mood, concentration).…”

Section: Instrumentsmentioning

confidence: 99%

Short-term efficacy of a fixed association of Palmitoylethanolamide and other phytochemicals as add-on therapy in the management of chronic pain in elderly patients: a real-world retrospective study

et al. 2018

View full text Add to dashboard Cite

Phytochemicals are promising adjuvant agents for the treatment of pain. This study aimed to explore the short-term efficacy and safety of a fixed-dose combined therapy with Palmitoylethanolamide and other phytochemicals as add-on therapy in elderly patients. Data on 47 elderly patients with non-oncologic chronic pain of mild-moderate degree were analyzed in a retrospective, descriptive, no-profit, double-center realworld study. Patients were administered the combined phytochemical therapy for 6 weeks, in addition to analgesics administered when needed. Patients showed a reduction in pain intensity both in mixed /nociceptive and in neuropathic pain and improvements in functional abilities, quality of life, and in the subjective belief about the efficacy of treatment. These results were also observed in the small subgroup of patients in monotherapy with phytochemicals (n=13). No adverse event led to treatment withdrawal. This exploratory study suggests that phytochemicals may represent an effective source of analgesics to be added to chemically synthesized drugs, therefore reducing the need of their up-titration and the risk of toxicity. These data must be considered as preliminary and need to be tested in randomized trials.

show abstract

A validation study of an Italian version of the brief pain inventory (Breve questionario per la valutazione del dolore)

Cited by 167 publications

References 13 publications

Chinese version of the M. D. Anderson Symptom Inventory

Chinese version of the M. D. Anderson Symptom Inventory

Racial differences in pain during 1 year among women with metastatic breast cancer

Short-term efficacy of a fixed association of Palmitoylethanolamide and other phytochemicals as add-on therapy in the management of chronic pain in elderly patients: a real-world retrospective study

Contact Info

Product

Resources

About